

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – UPDATE OF BUSINESS DEVELOPMENT WITH ITALFARMACO

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that on 30 December 2019, Lee’s Pharmaceutical (HK) Limited (“**LPHK**”), a wholly-owned subsidiary of the Company, its New Drug Application (“**NDA**”) of Teglutik® for the treatment of Amyotrophic Lateral Sclerosis (“**ALS**”) has been accepted for review by China’s National Medical Products Administration (“**NMPA**”).

Teglutik® is a licensed-in products from Italfarmaco S.A. (“**Italfarmaco**”), a specialty pharmaceutical company engaged in the discovery, development, manufacturing and marketing of branded prescription and non-prescription products in more than 60 countries on 5 continents, upon the signing of a distribution agreement therewith on 26 November 2019 which grants LPHK exclusive distribution rights to develop and commercialise Teglutik® in China, Hong Kong, Macau and Taiwan.

Furthermore, the Board of the Company is pleased to announce that an additional SKU of Ferplex® containing four vials per box will be launched in the first quarter of 2020 which may become new growth driver of the brand in the years to come. This is based on the extension of the exclusive distribution rights for Ferplex® granted by Italfarmaco in August 2019 in view of the long-standing distribution arrangement between Italfarmaco and LPHK which resulted in the continuous growth of Ferplex® in the Chinese market. The marketing territories of the product will also be expanded to include Hong Kong, Macau and Taiwan under the renewed arrangement. Through the Group’s newly established sales team for the OTC products, this additional SKU of Ferplex® will enhance the Group’s effort to extend the sales network and expand its coverage.

ABOUT TEGLUTIK®

Teglutik® (Riluzole) oral suspension is a neuroprotective agent indicated for the treatment of ALS. ALS is a fatal, adult-onset neurodegenerative disorder, which affects upper and/or lower motor neurons and is associated with degeneration of cortical and spinal motor neurons. Signs and symptoms of neurodegeneration are represented by progressive weakness of the bulbar, limb, thoracic and abdominal muscles. Cognitive dysfunction and dementia occur in 20-50% and 5-15% of cases, respectively. The disorder is one of the most common forms of Motor Neurone Disease (“MND”), representing more than 85% of all MND cases.

ABOUT FERPLEX®

Ferplex® is indicated for the treatment of severe and moderate iron deficiency conditions, such as latent or manifest iron deficiency anaemia, childhood and adulthood anaemia, anaemia caused by an insufficient intake or absorption of iron, anaemia secondary to acute or chronic bleeding or infectious diseases, and anaemia during pregnancy and lactation. In the Ferplex® compound, iron is bound to succinylated milk proteins, forming an iron-protein complex containing the equivalent of 40mg of trivalent iron. Due to its particular solubility profile, iron protein succinylate precipitates in the acidic environment of the stomach, keeping the iron bound to it. In this condition, the iron remains enclosed by the proteins, which prevent it from coming into direct contact with the mucous membrane of the stomach. The iron protein succinylate then resolubilises in the duodenum due to its alkaline pH, thus allowing the iron to be absorbed by the intestinal mucus while the protein component of the molecule is digested by the pancreatic protease. In clinical trials conducted on over 4,000 patients, through this specific mechanism, Ferplex® has been found to be well tolerated in the stomach in over 93% of cases.

By order of the Board of
Lee’s Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 6 February 2020

** For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.